This announcement is a separate document:
康哲藥業：自願性及業務進展公告 獲得治療白癜風、化膿性汗腺炎等適應症之口服小分子JAK1抑制劑Povorcitinib獨家許可權利
CMS: Voluntary and Business Update Announcement Gaining Exclusive License for Oral Small-molecule JAK1 Inhibitor Povorcitinib for the Treatment of Vitiligo and Hidradenitis Suppurativa and Other Indications
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.